Recent Updates
Recently added Catalysts

recombinant adenovirus-p53 SCH-58500

Phase 1

Fallopian Tube Cancer | Monoclonal antibody | Oncology |Merck & Company, Inc.|Last Updated: Feb 4, 2016

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment59
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00002960SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)PHASE1 COMPLETED 59Jun 1, 1999Jul 1, 2000Feb 4, 2016 -
Unlock Drug Trial Details
Study Design & Arms
PurposeTREATMENT
Interventions
NameTypeDescription
recombinant adenovirus-p53 SCH-58500BIOLOGICAL -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 120 Years
SexFEMALE
Healthy VolunteersNo

DISEASE CHARACTERISTICS: Radiographic or surgical evidence of primary ovarian, fallopian tube, or peritoneal carcinoma Ascites cytologically positive for peritoneal carcinomatosis from recurrent or persistent ovarian, fallopian tube, or peritoneal carcinoma Must have ascites and tumor accessible by ...

Unlock Eligibility Criteria